FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1986565282> ?p ?o ?g. }

• W1986565282 endingPage "463" @default.
• W1986565282 startingPage "453" @default.
• W1986565282 abstract "Neuroendocrine gut and pancreatic tumours have provided a diagnostic and therapeutic challenge over the years. These rather slowly growing neoplasms have been assigned a good prognosis but when liver metastases are present the prognosis is not better than that of most other malignant tumours. Despite the development of improved diagnostic procedures many patients are still referred at a stage of the disease too late for surgical cure, at which time medical treatment is warranted. The diagnosis is based on histopathological diagnosis including silver stainings (Grimelius, Masson) and immunohistochemistry for chromogranin A and synaptophysin. Analysis of chromogranin A in the plasma is an important adjunct in the screening for various types of neuroendocrine gut and pancreatic tumours. About 80%-100% of patients with verified neuroendocrine gastrointestinal tumours have elevated circulating levels of this glycoprotein. Depending on clinical symptoms the chromogranin A analysis is supplemented by other peptide hormone analyses as well as urinary 5-HIAA for patients with midgut carcinoid tumours. In the past the localization procedures were based on CT, MRI and ultrasound investigations but in recent years somatostatin receptor scintigraphy (octreoscan) and endoscopic ultrasonography have significantly improved the diagnostic potential. Almost 80% of neuroendocrine gastrointestinal tumours present somatostatin receptor subtype 2 binding 111Indium-labelled octreotide which can be used for staging of the disease, and which also indicates whether or not somatostatin analogues can be used in the treatment of these tumours. Surgery is still a cornerstone in the treatment of neuroendocrine gastrointestinal tumours, even if the patients are beyond cure. Debulking procedures and bypassing operations are important for improving clinical condition and facilitating impending medical treatment, and during the past decade a more aggressive surgical approach has emerged. The medical treatment is based on chemotherapy, and the use of somatostatin analogues and alpha-interferons. Chemotherapy, in particular the combination of streptozotocin with 5-FU or doxorubicin, is still first-line treatment for most endocrine pancreatic tumours, while somatostatin analogues and alpha-interferons are considered first-line for classical midgut carcinoids. Chemotherapy and biotherapy can be combined in many patients, and changes from one medical treatment to another during the course of the disease is mandatory for control of the disease. It is important to realise that most patients with malignant tumours are not cured by medical treatment but that the disease can be controlled for extended periods of time. In the future it will be possible to individualize treatments on the basis of new information about such features of tumour biology as proliferation capacity, expression of adhesion molecules, and growth factors and their receptors." @default.
• W1986565282 created "2016-06-24" @default.
• W1986565282 creator A5040645190 @default.
• W1986565282 date "1996-07-01" @default.
• W1986565282 modified "2023-10-03" @default.
• W1986565282 title "Neuroendocrine gastrointestinal tumours" @default.
• W1986565282 cites W148659409 @default.
• W1986565282 cites W1587263644 @default.
• W1986565282 cites W1589562115 @default.
• W1986565282 cites W1771569409 @default.
• W1986565282 cites W1922426788 @default.
• W1986565282 cites W1944616574 @default.
• W1986565282 cites W1963675975 @default.
• W1986565282 cites W1966669049 @default.
• W1986565282 cites W1967487654 @default.
• W1986565282 cites W1967612457 @default.
• W1986565282 cites W1969184550 @default.
• W1986565282 cites W1969880257 @default.
• W1986565282 cites W1970137427 @default.
• W1986565282 cites W1971066744 @default.
• W1986565282 cites W1972310983 @default.
• W1986565282 cites W1973024626 @default.
• W1986565282 cites W1975994802 @default.
• W1986565282 cites W1979524266 @default.
• W1986565282 cites W1979917113 @default.
• W1986565282 cites W1981515549 @default.
• W1986565282 cites W1984842005 @default.
• W1986565282 cites W1989883614 @default.
• W1986565282 cites W1994996206 @default.
• W1986565282 cites W2003424508 @default.
• W1986565282 cites W2011678905 @default.
• W1986565282 cites W2011739365 @default.
• W1986565282 cites W2014044771 @default.
• W1986565282 cites W2015951789 @default.
• W1986565282 cites W2017428584 @default.
• W1986565282 cites W2019769423 @default.
• W1986565282 cites W2022255159 @default.
• W1986565282 cites W2031807907 @default.
• W1986565282 cites W2032551896 @default.
• W1986565282 cites W2035527717 @default.
• W1986565282 cites W2036756177 @default.
• W1986565282 cites W2037349501 @default.
• W1986565282 cites W2039842131 @default.
• W1986565282 cites W2043754245 @default.
• W1986565282 cites W2045870790 @default.
• W1986565282 cites W2051530944 @default.
• W1986565282 cites W2055710544 @default.
• W1986565282 cites W2058650437 @default.
• W1986565282 cites W2061478913 @default.
• W1986565282 cites W2062809433 @default.
• W1986565282 cites W2063506925 @default.
• W1986565282 cites W2063862702 @default.
• W1986565282 cites W2066831496 @default.
• W1986565282 cites W2073051393 @default.
• W1986565282 cites W2077123274 @default.
• W1986565282 cites W2078148103 @default.
• W1986565282 cites W2080222082 @default.
• W1986565282 cites W2081457024 @default.
• W1986565282 cites W2083289293 @default.
• W1986565282 cites W2086133857 @default.
• W1986565282 cites W2091065621 @default.
• W1986565282 cites W2102980902 @default.
• W1986565282 cites W2104996454 @default.
• W1986565282 cites W2106608006 @default.
• W1986565282 cites W2113286278 @default.
• W1986565282 cites W2120460133 @default.
• W1986565282 cites W2120564716 @default.
• W1986565282 cites W2124918726 @default.
• W1986565282 cites W2151595903 @default.
• W1986565282 cites W2155644607 @default.
• W1986565282 cites W2157199565 @default.
• W1986565282 cites W2159331540 @default.
• W1986565282 cites W2227137721 @default.
• W1986565282 cites W2277473033 @default.
• W1986565282 cites W2319457872 @default.
• W1986565282 cites W2320542643 @default.
• W1986565282 cites W2331204701 @default.
• W1986565282 cites W2337046339 @default.
• W1986565282 cites W2337135362 @default.
• W1986565282 cites W2337686867 @default.
• W1986565282 cites W2339290868 @default.
• W1986565282 cites W2340185896 @default.
• W1986565282 cites W3160638549 @default.
• W1986565282 cites W4239520211 @default.
• W1986565282 doi "https://doi.org/10.1093/oxfordjournals.annonc.a010633" @default.
• W1986565282 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/8839899" @default.
• W1986565282 hasPublicationYear "1996" @default.
• W1986565282 type Work @default.
• W1986565282 sameAs 1986565282 @default.
• W1986565282 citedByCount "99" @default.
• W1986565282 countsByYear W19865652822012 @default.
• W1986565282 countsByYear W19865652822013 @default.
• W1986565282 countsByYear W19865652822014 @default.
• W1986565282 countsByYear W19865652822017 @default.
• W1986565282 countsByYear W19865652822019 @default.
• W1986565282 crossrefType "journal-article" @default.
• W1986565282 hasAuthorship W1986565282A5040645190 @default.
• W1986565282 hasBestOaLocation W19865652821 @default.

• next